MPL and autoimmune thrombocytopenic purpura: This case highlights a serious complication of eltrombopag therapy and underscores the need for vigilant monitoring of platelet counts, timely dose adjustment, and early recognition of thrombotic events in patients with ITP receiving thrombopoietin receptor agonists.